Bbi Holdings Share Discussion Threads

[chapman123] 22/2/2005 10:43

now 92-95 whats driving it ?

[chapman123] 21/2/2005 16:03

just moved now 87-90p was this on the back of the Legal and general news or something else not much volume around ?

[alftupper] 21/2/2005 15:20

You never know - a good company overall

[chapman123] 21/2/2005 13:41

seems to be hanging onto the gains expect an update from whatshot.com soon
which could move it near 100p ???

[alftupper] 18/2/2005 09:31

It is finally being recognised as a good quality AIM share - see the Times today

[chapman123] 10/2/2005 13:04

going well so far today forgot to mention 20% last two days

[chapman123] 10/2/2005 13:03

been tipped i understand with a target of 100p any more info ???

[jgoold] 09/2/2005 13:57

Having read it i more detail BBI looks v interesting. Are you holders?

[jgoold] 09/2/2005 13:38

It's on www.watshot.com. I'm afraid I can't cut and paste it but some v positive and looking for a share price of 100p

[egreensh] 09/2/2005 11:36

a tip on a web site

[abcd1234] 09/2/2005 11:12

whats moving it this a.m. ??

tia

[alftupper] 29/8/2004 10:12

Some day some one will waken up to the BBI opportunity - they made an announcement last week see below



LONDON (AFX) - BBI Holdings PLC, which listed on AIM in April, made a
"positive start to the year", chairman David Evans said in an AGM statement,
adding that sales continued to rise, driven by positive trading and progress
across all three of the company's core areas.
Cardiff, Wales-based BBI, which develops and manufactures rapid result
non-evasive diagnostic tests -- In Vitro Diagnostics -- has seen a "significant
growth" in manufacturing test volumes. Options to expand the business to meet
demand are being considered, it said.
"We are on track to achieve the key milestones we set out at the beginning
of the financial year, and with a strong, profitable, cash generative core
business we, remain confident about the company's prospects moving forward,"
Evans said.
[e-mail]
ab

[alftupper] 07/8/2004 14:07

Two director buys - am I the only one following this stock ?




RNS Number:5675B
BBI Holdings PLC
03 August 2004

BBI HOLDINGS PLC
03 AUGUST 2004

DEALINGS BY DIRECTORS


1) NAME OF COMPANY
BBI HOLDINGS PLC


2) NAME OF DIRECTOR
KEVIN WILSON


3) Please state whether notification indicates that it is in respect of
holding of the director named in 2 above or holding of that person's spouse or
children under the age of 18 or in respect of a non-beneficial interest
Director's holding


4) Name of the registered holder(s) and, if more than one holder, the number
of shares held by each of them (if notified)
Director named in 2 above


5) Please state whether notification relates to a person(s) connected with
the director named in 2 above and identify the connected person(s)
N/A


6) Please state the nature of the transaction. For PEP transactions please
indicate whether general/single co PEP and if discretionary/non discretionary
PURCHASE OF 40,000 ORDINARY 2.5P SHARES


7) Number of shares/amount of stock acquired
40,000


8) (0.188 %)
of issued class


9) Number of shares/amount of stock disposed
N/A


10) (0.00%)
of issued class


11) Class of security
Ordinary shares of 2.5p each


12) Price per share
51p


13) Date of transaction
02 AUGUST 2004


14) Date company informed
02 AUGUST 2004


15) Total holding following this notification
146,000


16) Total percentage holding of issued class following this notification
0.685%

ADDITIONAL INFORMATION


1) Name of contact and telephone number for queries
STEPHEN YOUNG 02920 747 232


2) Name and signature of authorised company official responsible for making
this notification
STEPHEN YOUNG 02920 747 232


Date of notification
03 AUGUST 2004



DEALINGS BY DIRECTORS


1) NAME OF COMPANY
BBI HOLDINGS PLC


2) NAME OF DIRECTOR
DAVID EVANS


3) Please state whether notification indicates that it is in respect of
holding of the director named in 2 above or holding of that person's spouse or
children under the age of 18 or in respect of a non-beneficial interest
Director's holding


4) Name of the registered holder(s) and, if more than one holder, the number
of shares held by each of them (if notified)
Director named in 2 above


5) Please state whether notification relates to a person(s) connected with
the director named in 2 above and identify the connected person(s)
N/A


6) Please state the nature of the transaction. For PEP transactions please
indicate whether general/single co PEP and if discretionary/non discretionary
PURCHASE OF 9,890 ORDINARY SHARES OF 2.5P EACH FOR DAVID EVANS' PENSION FUND


7) Number of shares/amount of stock acquired
9,890


8) (0.046 %)
of issued class


9) Number of shares/amount of stock disposed
N/A


10) (0.00%)
of issued class


11) Class of security
Ordinary shares of 2.5p each


12) Price per share
49.5p


13) Date of transaction
02 AUGUST 2004


14) Date company informed
02 AUGUST 2004


15) Total holding following this notification
313,294


16) Total percentage holding of issued class following this notification
1.469%


ADDITIONAL INFORMATION


1) Name of contact and telephone number for queries
STEPHEN YOUNG 02920 747 232


2) Name and signature of authorised company official responsible for making
this notification
STEPHEN YOUNG 02920 747 232


Date of notification
03 AUGUST 2004

END

Signed for and on behalf of and authorised for release



Stephen Young

[alftupper] 02/8/2004 10:40

RNS Number:4888B
BBI Holdings PLC
02 August 2004





For immediate release Monday, 2nd August 2004



BBI SIGNS LICENSING AGREEMENT FOR RAPID DETECTION LABORATORY TEST FOR 'SUPER BUG'


BBI Holdings PLC, the Cardiff based AIM listed point of care diagnostics
company, today announced that it has licensed out its isothermal nucleic acid
technology to ImmunoDiagnostic Systems Limited ("IDS") a developer, manufacturer
and marketer of immunoassay kits.


BBI's isothermal nucleic acid technology will be developed further by IDS to
take an asset acquired by BBI from Cytocell Limited in February 2003 for the
rapid detection of Methicillin-Resistant Staphylococcus aureus (MRSA), commonly
referred to as the 'Super Bug', through to commercial use in a format suitable
for routine use.


In addition to the proposed launch of the MRSA test in 2005 IDS is hoping to
develop further tests for Hospital Acquired Infections and aims to have a test
for VRSA (ancomycin Resitant Staph aureus) in 2006, the latter starting to
appear in hospitals with a more deadly threat than MRSA.


The new test will considerably reduce the time it takes to obtain a result,
just three-and-a-half hours after an overnight enrichment culture. . Current
results on patients screened for MRSA are generally not available for between
forty-eight to seventy-two hours (source: Journal of Clinical Microbiology, July
2003, p. 3187) resulting in reduced patient throughput, considerable disruption
and substantial extra costs to hospitals.


This announcement comes soon after a National Audit Office (NAO) survey reported
that hospital acquired infections, such as MRSA, are costing the NHS #1 billion
a year, in terms of additional treatment and ward closures. The NAO also
estimated that around 5,000 Britons die each year to infections acquired in
hospitals.


MRSA is a form of Staphylococcus aureus (SA), the most common type of bacteria
which can infect humans. About a third of the population are colonised with
them, however the bacteria becomes a higher risk when found in hospitals where
there is a concentration of the elderly and weak.



Julian Baines, Managing Director BBI Holdings PLC, commented:


"We are delighted to have reached an agreement with IDS that will allow the
technology and the test for MRSA to be developed for laboratory use whilst we
remain focussed on our point of care activities."


Dr Roger Duggan, Managing Director of IDS Limited, added:


"The MRSA rapid screening test will be the first of a number of products we
will develop using BBI's technology, and we hope to have this important tool
into hospital laboratories nationwide before the end of next year. There is no
doubt that easier and more rapid detection methods will help enormously in the
fight against MRSA"



- ends -


For further information please contact:

Julian Baines, Managing Director
BBI Holdings PLC
02920 747232
07788 420859


James Chandler/Mike Wort/John Moriarty
Beattie Financial
020 7398 3300

[alftupper] 23/7/2004 15:54

A good write up in EBG's epidermus report.

[alftupper] 17/7/2004 17:11

BBI came to market at the end of April and posted its results this week.It is a company involved in point of care diagnostics and is well worth looking at.